-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2022-501132-42-00
6
2022-08-02
Monkeypox virus disease
-
2024-511706-23-00
4
2022-05-31
Focal segmental glomerulosclerosis
-
2024-511996-13-00
5
2022-05-11
Previously untreated, unresectable, or metastatic melanoma
-
2024-513229-22-00
4
2022-04-21
Advanced cutaneous melanoma and Advanced mucosal melanoma
-
2023-504825-38-00
4
2022-04-15
Lupus Nephritis (LN)
Immunoglobulin A Nephropathy (IgAN)
-
2023-503572-24-00
5
2022-03-02
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-518915-20-00
6
2022-02-16
Type 2 diabetes mellitus
-
2023-510230-84-00
5
2021-05-28
Severe asthma with an eosinophilic phenotype
-
2023-505787-11-00
5
2021-04-29
Severe and inadequately controlled asthma
-
2023-509513-36-00
4
2021-03-24
Melanoma (Stage III and IV)
-
2023-508443-40-00
5
2020-12-18
Lung Cancer, Non-Small Cell
-
2023-506724-85-00
5
2020-11-19
Migraine
-
2023-506253-38-00
5
2020-11-09
Migraine
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2023-505035-12-00
5
2020-06-12
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
-
2023-504036-17-00
5
2020-05-07
Chronic Lymphocytic Leukemia (CLL)
-
2024-512537-33-00
5
2019-11-28
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
-
2023-505614-17-00
5
2019-09-20
Participants with advanced or recurrent endometrial carcinoma
-
2022-501439-18-00
5
2019-06-26
NSCLC with squamous or nonsquamous histology
-
2024-518179-76-00
4
2019-03-11
Calcagno stop and inguinal hernia repair
-
2022-500395-57-00
5
2019-03-04
Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2023-505494-32-00
5
2018-10-15
Focal segmental glomerulosclerosis (FSGS)